Hainsworth J D, Greco F A
Important Adv Oncol. 1991:173-90.
Advances in the management and treatment of the large, heterogeneous population of patients with carcinoma of unknown primary site have been achieved by recognizing treatable subsets within this group. Each of these subsets has been thoroughly discussed; Table 10-9 summarizes the treatable subsets and the evaluations necessary for their identification. Even within treatable subsets, treatment data remain limited, and optimal therapy is still evolving. Despite these advances, a large group of patients with relatively insensitive tumors remains. Improved therapy for these patients will probably await therapy breakthroughs in the treatment of non-small cell lung cancer, pancreatic cancer, and the various other GI malignancies, since these tumors represent the majority of occult primary sites.
通过识别不明原发部位癌这一庞大异质性患者群体中的可治疗亚组，在该群体的管理和治疗方面已取得进展。这些亚组中的每一个都已得到充分讨论；表10 - 9总结了可治疗亚组及其识别所需的评估。即使在可治疗亚组中，治疗数据仍然有限，最佳治疗方案仍在不断发展。尽管取得了这些进展，但仍有一大群患有相对不敏感肿瘤的患者。对这些患者的治疗改进可能有待于非小细胞肺癌、胰腺癌和其他各种胃肠道恶性肿瘤治疗方面的突破，因为这些肿瘤占隐匿原发部位的大多数。
